RUBENS

A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

Obicetrapib 10 mg + ezetimibe 10 mg FDC dailyOngoingRecruitingPhase 3Open NCT07219602 on ClinicalTrials.gov ↗

Population

Loading…

Intervention

Loading…

Comparator

Loading…

Loading…

RUBENS · Trial Tracker · ComplyRx